Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | CASR | P41180 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | GNRHR | P30968 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11080613 | 0.91 | TAAR1 (0.51) | AOC3L3MBTL1TAAR1CASRALDH1A1 | |
| SCHEMBL19791997 | 0.86 | AOC3 (0.50) | AOC3L3MBTL1TAAR1CASRALDH1A1 | |
| SCHEMBL21507667 | 0.86 | AOC3 (0.50) | AOC3L3MBTL1TAAR1CASRALDH1A1 | |
| SCHEMBL1473114 | 0.86 | AOC3 (0.53) | AOC3L3MBTL1TAAR1CASRALDH1A1 | |
| SCHEMBL24527630 | 0.85 | AOC3 (0.53) | AOC3L3MBTL1TAAR1CASRMTNR1A | |
| SCHEMBL382558 | 0.85 | AOC3 (0.53) | AOC3L3MBTL1TAAR1CASRMTNR1A | |
| SCHEMBL14312520 | 0.82 | AOC3 (0.53) | AOC3L3MBTL1TAAR1CASRALDH1A1 | |
| SCHEMBL355086 | 0.82 | AOC3 (0.53) | AOC3L3MBTL1TAAR1CASRALDH1A1 | |
| SCHEMBL17976247 | 0.82 | AOC3 (0.53) | AOC3L3MBTL1TAAR1CASRALDH1A1 | |
| SCHEMBL21507526 | 0.82 | AOC3 (0.52) | AOC3L3MBTL1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569337-B2 | Labeling brain tissues in vivo or in vitro; 3-Benzothiazol-2-yl-7-[4-(2-fluoro-ethyl)-piperazin-1-yl]-chromen-2-one; diagnosis, monitoring the effectiveness of a therapeutic treatment and detecting histopathological hallmarks of Alzheimer's disease | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| EP-1483262-B1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-20050169837-A1 | Coumarines useful as biomarkers | NOVARTIS AG (CH) | 2005-08-04 | — | — | US | disclosed |
| EP-1483262-A1 | COUMARINES USEFUL AS BIOMARKERS | Novartis AG (CH) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074519-A1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050169837-A1 | Coumarines useful as biomarkers | CCNB1, CBR1, CYP1A1 | AOC3 1969/4885L3MBTL1 3440/4885TAAR1 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.